Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at BIO CEO & Investor Conference on Monday, Febr...
February 07 2018 - 10:30AM
Innovate Biopharmaceuticals, Inc. (Nasdaq:INNT) a clinical stage
biotechnology company focused on developing novel autoimmune and
inflammation therapeutics, announced company executives are
scheduled to present at the BIO CEO & Investor Conference on
Monday, February 12, 2018, at 3:30 PM ET in the Wilder presentation
room at the New York Marriott Marquis located at 1535 Broadway in
Times Square.
About Innovate Biopharmaceuticals, Inc.:
Innovate is a clinical stage biotechnology company focused on
developing novel autoimmune and inflammation therapeutic drugs.
Innovate’s lead drug candidate, larazotide acetate (INN-202), has a
mechanism of action which decreases intestinal permeability and
regulates tight junctions by reducing antigen trafficking across
intestinal epithelial cells. In several autoimmune diseases,
including celiac disease, nonalcoholic steatohepatitis (NASH),
inflammatory bowel diseases (IBD, Crohn’s disease and ulcerative
colitis), irritable bowel syndrome (IBS), type 1 diabetes mellitus
(T1DM), chronic kidney disease (CKD) and others, intestinal
permeability is increased, also referred to as “leaky gut,” and to
our knowledge, larazotide is the only drug in clinical testing
which reduces permeability.
In celiac disease, larazotide is the only drug which has
successfully met the primary endpoint with statistical significance
in a 342-patient Phase 2b efficacy clinical trial. Innovate
successfully completed the End of Phase 2 Meeting with the FDA in
2017 and is preparing for larazotide to begin Phase 3 clinical
trials for celiac disease around mid-2018. In clinical trials
testing more than 800 patients, larazotide demonstrated a favorable
safety profile comparable to placebo, especially due to its lack of
systemic absorption from the small intestines. Larazotide has also
received Fast Track designation from the FDA for celiac
disease.
Innovate Biopharmaceuticals, Inc.Kendyle
WoodardTel: 919-275-1933 x 1Email:
investor.relations@innovatebiopharma.com
www.innovatebiopharma.com
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Apr 2023 to Apr 2024